Clive Mccarthy

Milton Park
Abingdon, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo.

ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: February 05, 2024

Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.

Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.

Journal: Journal of medicinal chemistry

Published: May 02, 2022

TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis.

TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis.

Journal: American journal of respiratory and critical care medicine

Published: January 04, 2020

Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.

Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: January 21, 2016

Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).

Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).

Journal: Journal of medicinal chemistry

Published: August 20, 2015

Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.

Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.

Journal: Expert opinion on therapeutic patents

Published: May 09, 2014

The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.

The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.

Journal: Bioorganic & medicinal chemistry letters

Published: April 26, 2014

Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.

Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.

Journal: Journal of medicinal chemistry

Published: August 15, 2012

Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.

Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.

Journal: Bioorganic & medicinal chemistry letters

Published: June 06, 2012

Modulation of spontaneous activity in the overactive bladder: the role of P2Y agonists.

Modulation of spontaneous activity in the overactive bladder: the role of P2Y agonists.

Journal: American journal of physiology. Renal physiology

Published: February 24, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026